NOVADIGM THERAPEUTICS

NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in some cases, life-threatening. NovaDigm's lead development candidate, NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. A Phase 2 efficacy study of NDV-3A versus placebo in patients with recurrent vulvovaginal candidiasis (RVVC) demonstrated that a single dose of NDV-3A resulted in an increase in the recurrence-free rate out to 12 months and extended the time to first recurrence for those that had a recurrence. Clinical development has also begun to assess the potential impact of NDV-3A in the prevention of S. aureus skin and soft tissue infections. The Company's founding scientists from the Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA Medical Center are recognized leaders in the field of..

Also known as: NovaDigm Therapeutics, Inc.